Re: Rethinking neoadjuvant chemotherapy for breast cancer
CONCLUSIONS The findings of this study support a role for c-Met as a clinical prognostic marker and for c-Met and TOPO II as predictive markers for response to chemotherapy in patients with breast cancer. PMID: 30444219 [PubMed - in process]
Publication date: Available online 17 November 2018Source: Pathology - Research and PracticeAuthor(s): Li MaAbstractNeoadjuvant chemotherapy(NCT) has become the standard treatment for breast cancer. The information about the tumor’s sensitivity to chemotherapy and prognostic significance based on response to therapy can be provided after individualized neoadjuvant treatment. The biomarkers are key factors in the decision-making process regarding treatment as well as important prognostic indicators. Studies have shown that patients who achieve pathological complete response(pCR) after NCT have a better prognosis. For ...
Condition: Breast Cancer Interventions: Drug: Nivolumab 360 mg+ paclitaxel 80 mg/m2; Drug: Doxorubicin 60 mg/m2+Cyclophosphamide 600 mg/m2; Drug: Nivolumab 360 mg+ Docetaxel* 75 mg/m2 +Trastuzumab 8 mg/kg +Pertuzumab 840 mg; Drug: Doxorubicin 60 mg/m2 +Cyclophosphamide 600 mg/m2 Sponsor: New York University School of Medicine Not yet recruiting
Condition: Breast Neoplasm Interventions: Drug: AZD6738; Drug: Olaparib; Drug: Durvalumab Sponsors: Institute of Cancer Research, United Kingdom; AstraZeneca Not yet recruiting
ConclusionThis analysis represents the most comprehensive SLR/cNMA to date of published OS data in HER2+ EBC studies. These findings demonstrate why H/chemotherapy is now the established standard of care in HER2+ EBC. In the case of H, the benefits of early patient access far outweighed the risk of waiting for more precise information.Systematic review registrationPROSPEROCRD42017055763
Conclusion: Our analysis provides a rationale for the routine use of a radiopaque tissue transfer system for specimen radiography in BCS after neoadjuvant chemotherapy for invasive breast cancer in order to reduce re-excision rates.Breast Care
We report the case of a 68-year-old Caucasian female with a family history of cancer. Core biopsy revealed that she had grade II oestrogen receptor-negative, Her2-positive invasive ductal carcinoma. She was offered neoadjuvant chemotherapy with Herceptin and subsequently underwent breast-conserving surgery. Microscopic examination of the post-treatment breast surgical specimen showed a partial pathological response with large areas of tumour regression. The sentinel lymph node showed frequent large single and multinucleate giant cells with hyperchromatic nuclei located predominantly within the subcapsular and medullary sin...
This study aimed to develop mathematical tools to predict the likelihood of recurrence after neoadjuvant chemotherapy (NAC) plus trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.MethodsData of 776 patients from a multicenter retrospective cohort study were collected. All patients had HER2-positive breast cancer and received NAC plus trastuzumab between 2001 and 2010. Two mathematical tools using a machine learning method were developed to predict the likelihood of disease-free survival (DFS) (DFS model) and brain metastasis (BM) (BM model) within 5 years after surger...
Diana P. Saraiva, Ant ónio Jacinto, Paula Borralho, Sofia Braga, M. Guadalupe Cabral
CONCLUSIONS: This model could be a helpful tool for the surgeon to help in predicting which cases have a higher likelihood of achieving a pathologically complete response and therefore selecting those who may benefit from a post-neoadjuvant chemotherapy sentinel lymph node biopsy and avoid unnecessary axillary lymphadenectomy. PMID: 30421628 [PubMed - as supplied by publisher]